Healthcare Companies Announce Drug Launches, Upcoming Conference Calls, and Financial Results Schedules - Research Report on Bristol-Myers Squibb, Teva, Jazz, AmerisourceBergen and Arena

NEW YORK, January 9, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), AmerisourceBergen Corporation (NYSE: ABC), and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Bristol-Myers Squibb Company Research Report

On January 6, 2014, Bristol-Myers Squibb Company (Bristol-Myers Squibb) announced that it will report results for Q4 2013 and full-year 2013 on January 24, 2014. In addition, Bristol-Myers Squibb will hold a conference call at 10:30 a.m. EST on the same day, during which the Company's executives will review financial information and address inquiries from investors and analysts. The Company informed that the live webcast and its replay (available through 1:30 p.m. EST on February 7, 2014) will be accessible via its website. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/81a9_BMY

--

Teva Pharmaceutical Industries Limited Research Report

On January 3, 2014, Teva Pharmaceutical Industries Limited (Teva) announced the launch of the Authorized Generic of Detrol LA (tolterodine tartrate extended-release capsules) 2 mg and 4 mg in the US market. The Company stated that Detrol LA had annual sales of approximately $571.5 million in the US, according to IMS data as of September 30, 2013. The Full Research Report on Teva Pharmaceutical Industries Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e3a3_TEVA

--

Jazz Pharmaceuticals plc Research Report

On January 6, 2014, Jazz Pharmaceuticals plc (Jazz) announced that the Company will be webcasting its corporate presentation at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Jazz reported that Bruce C. Cozadd, Chairman and CEO, will provide an overview of the Company and provide a business and financial update at the conference on January 13, 2014 at 10:00 a.m. PST. Jazz informed that a live audio webcast of the presentation may be accessed from the Investors section of its website. The Full Research Report on Jazz Pharmaceuticals plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5fe3_JAZZ

--

AmerisourceBergen Corporation Research Report

On January 6, 2014, AmerisourceBergen Corporation (AmerisourceBergen) announced that it will be attending the J.P. Morgan Healthcare Conference on January 14, 2014, and will be presenting at 2:00 p.m. PST. AmerisourceBergen continues to expect adjusted earnings per share from continuing operations in the range of $3.60 to $3.73 for full-year FY 2014. The Company plans to release its financial results for Q1 FY 2014 on January 23, 2014. The Full Research Report on AmerisourceBergen Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/29fb_ABC

--

Arena Pharmaceuticals, Inc. Research Report

On January 6, 2014, Arena Pharmaceuticals, Inc. (Arena Pharmaceuticals) announced that the Company is scheduled to present a corporate overview at the 32nd Annual J.P. Morgan Healthcare Conference on January 13, 2014, at 1:30 p.m. PST at The Westin St. Francis Hotel in San Francisco, California. The Company informed that a live audio webcast of the presentation will be available under the investor relations section of Arena's website and a replay of the presentation will be available for 30 days following the event. The Full Research Report on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/6a95_ARNA

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsCorner.com

SOURCE Analysts' Corner